Latest news with #MemorialSloanKettering
National Post
a day ago
- Business
- National Post
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 2030
Article content CHICAGO — Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. Article content 'Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,' said Miguel Perales, MD, Chief, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center (MSK); Past President, American Society for Transplantation and Cellular Therapy (ASTCT); and Co-Chair, CAR T Vision Steering Committee. 'When it comes to treating these potentially deadly cancers, every minute counts. That is why we established CAR T Vision with recommendations for interventions that, when adopted and scaled, will help many more eligible patients get the opportunity for cure within the next five years.' Article content The roadmap report, developed by an independent Steering Committee comprised of leadership from top North American and European patient advocacy groups, medical society organizations, academic and community treatment centers, health technology assessment, policy, and other subject matter experts, provides the foundations for advocacy and action by local stakeholders to address the specific access challenges patients face in different geographies. Building on the report, expert Working Groups will be established to translate the Vision into concrete, measurable actions, including specific recommendations and a measurement framework to track progress. Article content 'Limited awareness of CAR T-cell therapy, low referrals, hospital capacity challenges, and funding and reimbursement are among the barriers that either prevent people from accessing CAR T-cell therapy altogether or cause delays that advance a patient's cancer beyond the point of treatment eligibility. In short, these barriers cost lives,' said Anna Sureda, MD, PhD, Clinical Hematologist, Professor and Cell Therapy Researcher; and Co-Chair, CAR T Vision Steering Committee. 'We call on every stakeholder and organization with the ability to help shape better patient outcomes—policymakers, health system leaders, payors, healthcare providers, patient advocates, and industry—to join the growing coalition of Vision endorsers and help ensure every eligible patient has the opportunity for cure with CAR T-cell therapy.' Article content Making CAR T Vision a reality will require the coming together of a complex ecosystem of partners, each with their own unique role to play. To learn more about CAR T Vision, review the roadmap report and join the coalition, visit Article content CAR T-cell therapy involves engineering a person's own immune cells to target and treat cancer and is currently approved for certain types of aggressive blood cancers, enabling some patients to remain cancer free for more than five years. 4,5,6,7 Article content The CAR T Vision is for every eligible patient to have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. The CAR T Vision Steering Committee includes leadership from top North American and European patient advocacy groups, medical society organizations, academic and community treatment centers, health technology assessment, policy, and other subject matter experts. The new roadmap report details the challenges CAR T Vision aims to resolve through multidisciplinary collaboration and the urgent actions needed to make the Vision a reality. The report and initial activities of the CAR T Vision Steering Committee have been funded by Gilead Sciences and Kite, as the inaugural supporter of CAR T Vision. Report content has been reviewed by Gilead Sciences and Kite. However, the Steering Committee has editorial control of the CAR T Vision and its outputs, including the report. Dr. Perales has financial interests related to Gilead Sciences and Kite. To learn more about CAR T Vision, review the report and join the growing coalition of endorsers, visit Article content 2 Chuhara, D, Liao, L, et al. Real-world experience of CAR T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma. Blood. 2023, September 21. Article content 3 Canales Albendea MÁ, Canonico PL, Cartron G, et al. Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries. Front Med (Lausanne). 2023;10:1128295. Published 2023 May 30. doi:10.3389/fmed.2023.1128295 Article content 4 Abramson J, Palomba ML, Gordon LI, et al. Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL). Blood. 2024;144(1):3125. Article content 5 Neelapu SS, Jacobson CA, Ghobadi A, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023 May 11;141(19):2307-2315. doi: 10.1182/blood.2022018893. PMID: 36821768; PMCID: PMC10646788. Article content 6 Rives S, Maude S, Hiramatsu H et al. S112: TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL): FINAL ANALYSES FROM THE ELIANA STUDY. HemaSphere 6():p 13-14, June 2022. | DOI: 10.1097/ Article content Article content Article content Article content Article content Article content
Yahoo
5 days ago
- Business
- Yahoo
Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has presented the early-stage clinical data from its GD2-SADA PRIT trial at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C. The presentation marks a significant update in its experimental pipeline. The trial-in-progress poster contained findings from Trial 1001, a Phase 1 study assessing GD2-SADA Pretargeted Radioimmunotherapy using 177Lu-DOTA in patients with high-risk neuroblastoma and other GD2-expressing tumors. A scientist in a lab coat, holding a beaker of a biopharmaceutical creation. The focus of the company's presentation was on radioimmunotherapy innovation. The GD2-SADA construct, developed in a partnership with Memorial Sloan Kettering Cancer Center, deploys a two-step process allowing localized irradiation of tumors while limiting off-target toxicity. Trial 1001 has now completed Part A and has identified the optimal dosage for the GD2-SADA protein. It is currently being prepared for further evaluation. Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has scheduled to deliver its initial data readout during its virtual R&D update on May 28. The company's stock gained 5.37% in the past week right before the new unveiling, reflecting investor confidence in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)'s proprietary Self-Assembly DisAssembly (SADA) platform as well as the upcoming clinical milestones. Analysts remain bullish, offering a consensus Buy rating, while projecting an average price target of $16.50 with an upside potential of 281.94%. While we acknowledge the potential of YMAB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than YMAB and that has 100x upside potential, check out our report about the READ NEXT: 10 Unstoppable Dividend Stocks to Buy Now and 11 Oversold Global Stocks to Buy According to Hedge Funds Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Daily Mail
5 days ago
- Health
- Daily Mail
Doctor issues cancer warning over popular quick dinner - 'it could increase risk by 55%'
It's a cheap student staple that makes an speedy lunch or tasty snack. But regularly consuming instant noodles could be wreaking havoc on your health, dramatically raising the risk of deadly stomach cancer, according to top oncology medic, Dr Tim Tiutan. Processed foods packed with salt have been vilified for decades over their supposed risks, with dozens of studies linking them to type 2 diabetes and other conditions including heart attacks and strokes. Yet, instant noodles, like many other salt-laden processed foods, could also raise cancer risk by leaving the stomach more prone to the cancer-causing bacteria Helicobacter pylori (H. pylori), the internal medicine doctor at Memorial Sloan Kettering Cancer Centre in New York, said. In an Instagram reel watched more than 88,000 times, Dr Tiutan told his followers: 'High salt diets can increase cancer risk by disrupting your stomach lining and fueling H. pylori infections—a major driver of stomach cancer. 'Excessive salt is associated with increasing stomach cancer risk by 55 per cent and may even double the risk when H. pylori is present. 'So, reduce your salt intake to one teaspoon per day and try to eat high salt foods like these sparingly. 'Bacon, ham, hot dogs, sausages, deli meats, preserved foods, canned soups, instant noodles.' He added: 'This isn't about fear-mongering. Small diet changes can lower cancer risk. Sodium is essential to life, but too much can be harmful. 'High salt intake leads to hypertension and other chronic medical conditions too. 'Sometimes health providers ask patients to take in more salt for various medical reasons, which people should follow.' Doctors have for years warned that consuming too much salt can ultimately lead to health conditions including heart attacks and strokes. The NHS recommends adults should have no more than 6g—around one teaspoon—of salt a day. But research suggests adults consume up to ten times the amount of sodium—the metallic element in salt—required for their metabolisms every day. H. pylori, or Helicobacter pylori, is a type of bacteria that 40 per cent of people carry in their stomach. In between 80 and 90 per cent of cases it doesn't cause symptoms, however it can trigger stomach ulcers, indigestion, bloating or nausea. H. pylori can be detected with a blood, breath or stool sample test—and treated with antibiotics and other medicines. It has long been known that excessive salt intake can worsen H. pylori infection—one of the strongest known risk factors for stomach cancer. Other factors including smoking can also raise the risk of H. pylori leading to cancer, according to Cancer Research UK. Research published last year assessing salt and stomach cancer risk among more than 470,000 UK adults found regular use at the table could increase the risk by up to 41 per cent compared to those who rarely or never add salt. Another in the British Journal of Cancer also concluded people who consistently eat highly salted foods may double their risk of stomach cancer. It comes as scientists last year sounded the alarm over the 'disturbing' rise in young adults with stomach cancer. Although cases are falling in older people, in the past few years has been an annual two per cent uptick in under 50s being diagnosed, leaving experts baffled. Worryingly, in half of these cases the cancer is already advanced—meaning it is 'almost a death sentence', with just a four per cent survival rate. About 6,500 patients in Britain and 30,000 in the US are diagnosed with stomach cancer each year. The disease kills roughly 4,000 Britons and 11,000 Americans every year. If caught in its earliest stages, the majority of stomach cancer patients (65 per cent) will survive a decade after their diagnosis according to charity Cancer Research UK. However, for stage four patients, 10-year survival drops to just one in five. Common symptoms of the condition include indigestion, lack of appetite, a feeling of fullness, bleeding, blood in the stools, blood clots or sickness. The UK is the worst in Europe for eating salt-laden ultra-processed foods (UPFs), which make up an estimated 57 per cent of the national diet. The umbrella term UPFs is used to cover anything edible made with colourings, sweeteners and preservatives that extend shelf life. They are thought to be a key driver of obesity, which costs the NHS around £6.5billion a year treating weight-related disease like diabetes, heart disease and some cancers. Last year, disturbing data also suggested that children who ate lots of UPFs show early signs of poor heart health and diabetes risk factors from as young as three years old.
New York Post
23-05-2025
- Health
- New York Post
Memorial Sloan Kettering prom gives kids with cancer a chance to celebrate: ‘I feel like a queen'
After being diagnosed with an aggressive and rare carcinoma tumor during her sophomore year in March, 16-year-old Jazzy missed her prom. Advertisement But, on Thursday afternoon, the Catskill teen got to walk a red carpet in a pink-beaded ball gown, pose for pics with new bestie and fellow patient Samantha,15, and boogie to 'Shout' and 'Dancing Queen' with her high school boyfriend Liam. 'We get to have our own little prom here,' said Jazzy, who is facing hearing loss from her chemotherapy. 'We have a new family here.' 8 Jazzy (left) and Samantha were thrilled to attend prom at Memorial Sloan Kettering. Tamara Beckwith Advertisement She was one of about 200 people —glammed up patients, families and staffers – in attendance at Memorial Sloan Kettering's Pediatric Prom, which was held in the transformed West Dining Room inside the renowned hospital. It was the 35th Pediatric Prom, which started as a small dance party in the hospital unit and has grown to an elaborate ball with fancy dresses, a photo booth, DJs, limos, a milk-and-cookies bar, face paint and lots of dancing. 'Our entire team is committed to making it a special and memorable day for everyone involved,' Rachel Corke, the director of hospital administration for MSK Kids, told The Post. 8 Staffers dress up and attend the prom alongside patients. Tamara Beckwith Advertisement Against the backdrop of glittery 'Starry Night' themed decorations, guests sipped ginger ale and juice and enjoyed mac and cheese and burgers that even the doctors OK'ed just this once. 'I don't feel like a princess — I feel like a queen,' exulted 7-year-old Maya in between bites of freshly popped popcorn from a festive cart. The tiara-clad tot has been battling neuroblastoma since she was 3 and underwent surgery two years ago to remove a tumor. Hospital staff danced alongside their brave young charges. 8 Patient Gini Beltran attended the event with fiance Juan Guillermo. Tamara Beckwith Advertisement 'This is everyone's favorite day of the year,' said Melissa Seidner, a 31-year-old administrative supervisor in the pediatric division at MSK. 'It's so fun to see all the patients enjoy themselves. It's a nice break from dealing with what we deal with.' She wore a jewel green gown that she'd selected from racks of donated dresses in a repurposed hospital rec room turned into 'Promingdale's' by the Society of MSK's Children's Committee. Maggie Kraus, a 17-year-old from Westchester who was diagnosed with leukemia this past November, rocked a soft purple frock with matching head scarf as she partied the afternoon away. 'I love princess dresses,' she said, vowing to wear it for her upcoming 18th birthday in July. 'I was really nervous I wouldn't be able to experience senior prom. But they pulled through.' 8 The Society of MSK's Children's Committee creates a 'Promingdale's' shop in a repurposed hospital rec room. Doree Lewak for NY Post 8 Patients and staffers get to choose from racks of donated clothing. Doree Lewak for NY Post Kraus was set to start her next round of chemo a few hours after prom, but she didn't let it — and the nausea it would likely bring about — take away from her enjoyment of the event. 'Let me have fun,' she said. Advertisement As the song 'I Will Survive' played poignantly in the background, the competitive equestrian relayed how her 'whole world got turned upside down' by her recent diagnosis. Doctors told her she wouldn't be able to ride horses for two years. 'I proved them wrong and I'm riding,' said the fearless teen, who volunteers to work with younger kids on the spectrum. 'I'm super-scared of needles, but I have to get used to it.' 8 Maggie Kraus was thrilled to find a violet gown. Tamara Beckwith Advertisement She shaved off her flowing brown hair — which she loved to dye bright colors — rather than waiting for the side effects of chemo to cause it to fall out. 'I wanted it to be my doing and not the cancer,' she said. Pediatric oncologist Dr. Andrew Kung told The Post that the prom exemplifies the philosophy at MSK, whose pediatric cancer center is ranked the best in the country and treats people up to age 40. 'This is one of the most special events for us,' he said. '[We're] not just about curing disease but caring for the patient and family.' Advertisement 8 The Rodriguez family — 6-year-old Alessia (second from left), mom Maite, dad Diego and little sister Vida — had a great time at the event. Tamara Beckwith 8 Jon Lyrick hopes to one day volunteer at the event. Tamara Beckwith Jon Lyrick was decked out in a show-stopping silver and black suit from Portabella. The 25-year-old from Crown Heights partied with friends as he told The Post that someday he'd 'love to come back to prom as a volunteer.' Advertisement Lyrick, who has undergone two bone marrow transplants, is feeling stronger every day. 'I love to have fun,' he told The Post between songs on the dance floor, where he happily spun around friends and IV poles. 'Today is a good day.'
Yahoo
21-05-2025
- Health
- Yahoo
Joe Biden was last screened for prostate cancer in 2014 before diagnosis
WASHINGTON ― Joe Biden's last known blood test to screen for prostate cancer was in 2014, seven years before he became president, a spokesperson for the former president confirmed to USA TODAY. Biden, who was diagnosed with an aggressive form of prostate cancer on Friday, May 16, took an annual physical in each of his four years as president. But in accordance with medical guidelines for seniors, none of the check ups included a PSA test that measures the prostate-specific antigen to screen for prostate cancer. The influential U.S. Preventive Services Task Force recommends that men 55 to 69 years old should consider periodic PSA testing in consultation with their doctor about the potential benefits and harms. But because prostate cancer is typically so slow-growing, the task force does not recommend routine screening for men 70 or older. Potential risks at that age are considered to outweigh the advantages of the screenings, including false positives, detecting cancers that aren't deadly, unnecessary biopsies or treatments, and patient anxiety. Biden's most recent PSA test in 2014 took place when was vice president and 72 years old. Biden, who is now 82, was diagnosed on May 16 with prostate cancer that had spread to the bone after a nodule was discovered on his prostate following urinary symptoms, a spokesperson said. More: Biden has an aggressive form of prostate cancer. Should it have been caught earlier? Biden has a Gleason score of 9 and a grade group 5, which is on the higher end of the scale, meaning the cancer is more likely to grow and spread quickly. Biden's cancer is considered stage 4, the most advanced stage of cancer that is characterized by spreading to other parts of the body. Given Biden's age, medical experts say Biden didn't require regular screening for prostate cancer to receive top medical care. "He could be receiving the best medical care that we have to offer as a nation and not be screened for prostate cancer," said Dr. Michael Morris, a Memorial Sloan Kettering oncologist who specializes in treating men with prostate cancer. "Excellent care means not under-testing. It also means not over-testing." More: 'Need to be honest': Vance questions Biden's health as president after cancer diagnosis Yet prostate cancer is typically detected at an earlier stage. Dr. Herbert Lepor, a urologist at NYU Langone Health, told Reuters that given the available screening options, 'it is a bit unusual in the modern era to detect cancers at this late stage.' Biden's most recent annual physical as president ‒ which did not include prostate cancer screening ‒ took place in February 2024. The president's physician, Dr. Kevin O'Connor, described Biden as a "healthy, active, robust 81-year-old male who remains fit to successfully execute the duties of the Presidency." The report cited Biden's sleep apnea treatment and stiffened gait from arthritis. Reach Joey Garrison on X @joeygarrison. This article originally appeared on USA TODAY: Biden was last screened for prostate cancer in 2014 before diagnosis
